Marinus Pharmaceuticals, Inc. (MRNS)
Feb 11, 2025 - MRNS was delisted (reason: acquired by Immedica)
0.550
+0.001 (0.09%)
Inactive · Last trade price
on Feb 11, 2025
MRNS's stock price has decreased by -94.55% in the past year and price targets may not have had time to catch up.
Marinus Pharmaceuticals Analyst Ratings
Total Analysts
12
Consensus Rating
Buy
Price Target
$4.28
Upside
+678.18%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $4 | Buy | Reiterates | $4 | +627.27% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $2 | Hold | Reiterates | $2 | +263.64% | Nov 14, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 | Strong Buy | Maintains | $3 | +445.45% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 25, 2024 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 25, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $3 → $1 | Hold | Maintains | $3 → $1 | +81.82% | Oct 25, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $13 → $4 | Buy | Maintains | $13 → $4 | +627.27% | Oct 25, 2024 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $5 → $0.5 | Strong Buy → Hold | Downgrades | $5 → $0.5 | -9.09% | Oct 25, 2024 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 24, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $23 → $3 | Strong Buy | Maintains | $23 → $3 | +445.45% | Oct 24, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +4,081.82% | Oct 17, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +4,081.82% | Oct 11, 2024 |
| EF Hutton | EF Hutton | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +4,081.82% | Sep 30, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $13 | Buy | Reiterates | $13 | +2,263.64% | Sep 24, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +990.91% | Sep 23, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $10 | Buy | Reiterates | $10 | +1,718.18% | Sep 23, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.